Tango Therapeutics, Inc.
TNGX
$18.03
$0.734.22%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 48.29% | 53.28% | -42.84% | 10.10% | 15.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 48.29% | 53.28% | -42.84% | 10.10% | 15.18% |
| Cost of Revenue | -8.17% | -5.18% | 0.92% | 13.63% | 24.93% |
| Gross Profit | 31.49% | 31.08% | -20.99% | -15.13% | -29.46% |
| SG&A Expenses | -5.12% | 2.57% | 13.55% | 16.82% | 23.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.46% | -3.41% | 3.79% | 14.38% | 24.53% |
| Operating Income | 23.56% | 21.02% | -18.75% | -15.64% | -27.52% |
| Income Before Tax | 21.91% | 18.49% | -25.00% | -18.47% | -28.03% |
| Income Tax Expenses | -98.08% | -47.57% | -1.71% | 16.09% | 55.22% |
| Earnings from Continuing Operations | 22.03% | 18.54% | -24.96% | -18.46% | -28.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 22.03% | 18.54% | -24.96% | -18.46% | -28.07% |
| EBIT | 23.56% | 21.02% | -18.75% | -15.64% | -27.52% |
| EBITDA | 23.82% | 21.35% | -19.11% | -15.92% | -28.04% |
| EPS Basic | 28.07% | 21.77% | -17.33% | -7.26% | -9.47% |
| Normalized Basic EPS | 27.38% | 24.33% | -14.61% | -4.54% | -8.52% |
| EPS Diluted | 27.06% | 20.74% | -17.44% | -7.37% | -9.58% |
| Normalized Diluted EPS | 26.67% | 23.62% | -14.61% | -4.54% | -8.52% |
| Average Basic Shares Outstanding | 6.85% | 4.33% | 6.64% | 11.52% | 16.96% |
| Average Diluted Shares Outstanding | 8.43% | 5.94% | 6.64% | 11.52% | 16.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |